Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Genomics has greatly improved how patients with cancer are being treated; however,
clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole …

The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

Purpose Molecular diagnostic testing has become an integral part of the evaluation of
patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next …

Treatment of metastatic colorectal cancer is based upon the assumption that metastases are
homogeneous within a patient. We quantified immune cell types of 603 whole-slide …

Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15 …